Advertisement

Quantifying Allosteric Modulation of G Protein-Coupled Receptors

  • Frederick J. EhlertEmail author
  • Hinako Suga
Protocol
Part of the Neuromethods book series (NM, volume 60)

Abstract

In this chapter, methods for the analysis of allosterism in equilibrium binding and functional assays are described. The functional response to activation of a G protein-coupled receptor is usually measured at a point downstream from receptor activation in the signaling pathway, and the effects of allosteric modulation on the response can be attributed to scalar changes in the observed affinity (α) and intrinsic efficacy (β) of the agonist-receptor complex. If the concentration-response curve of the agonist is measured in the absence and presence of a range of concentrations of the allosteric modulator, then it is always possible to estimate the affinity constant of the modulator (K 2) and the product (γ) of the modulatory changes in the observed affinity and efficacy of the agonist-receptor complex (γ  =  a  β). In many instances, it is impossible through analysis of receptor function only to determine the α and β components of the modulation. Regardless, the parameter γ is unique in that it represents the ratio of the microscopic affinity constants of the modulator for the active and inactive states of the receptor in situations where there is one orthosteric activation site directly linked to the allosteric site. Radioligand binding assays can be used to estimate affinity modulation between the allosteric modulator and the orthosteric radioligand or another nonlabeled orthosteric ligand. By measuring allosterism in both functional and binding assays, it is possible to measure the affinity and efficacy components of allosteric modulation.

Key words

Allosterism Affinity Efficacy Modulation Pathway selectivity Ligand-directed signaling 

References

  1. 1.
    Ehlert FJ, Griffin MT (2008) Two-state models and the analysis of the allosteric effect of gallamine at the M2 muscarinic receptor. J Pharmacol Exp Ther 325:1039–1060.PubMedCrossRefGoogle Scholar
  2. 2.
    Stephenson RP (1956) A modification of receptor theory. Br J Pharmacol 11:379–393.Google Scholar
  3. 3.
    Furchgott RF (1966) The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv Drug Res 3:21–55.Google Scholar
  4. 4.
    Ehlert FJ (2005) Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315:740–754.PubMedCrossRefGoogle Scholar
  5. 5.
    Ehlert FJ (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33:187–194.PubMedGoogle Scholar
  6. 6.
    Christopoulos A (2000) Quantification of allosteric interactions at G protein-coupled receptors using radioligand binding assays. In: Enna SJ (ed) Current Protocols in Pharmacology. Wiley, New York.Google Scholar
  7. 7.
    Lazareno S, Birdsall NJ (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362–378.PubMedGoogle Scholar
  8. 8.
    Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1:198–210.PubMedCrossRefGoogle Scholar
  9. 9.
    Christopoulos A, Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323–374.PubMedCrossRefGoogle Scholar
  10. 10.
    Stockton JM, Birdsall NJ, Burgen AS et al (1983) Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 23:551–557.PubMedGoogle Scholar
  11. 11.
    Black JW, Leff P (1983) Operational models of pharmacological agonism. Proc Roy Soc Lond B 220:141–162.CrossRefGoogle Scholar
  12. 12.
    Marino MJ, Williams DL, O’Brien JA et al (2003) Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson’s disease treatment. Proc Natl Acad Sci USA 100:13668–13673.PubMedCrossRefGoogle Scholar
  13. 13.
    Suzuki G, Kimura T, Satow A et al (2007) Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N- methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J Pharmacol Exp Ther 321:1144–1153.PubMedCrossRefGoogle Scholar
  14. 14.
    Ehlert FJ (1988) Gallamine allosterically antagonizes muscarinic receptor-mediated inhibition of adenylate cyclase activity in the rat myocardium. J Pharmacol Exp Ther 247:596–602.PubMedGoogle Scholar
  15. 15.
    Candell LM, Yun SH, Tran LL et al (1990) Differential coupling of subtypes of the muscarinic receptor to adenylate cyclase and phosphoinositide hydrolysis in the longitudinal muscle of the rat ileum. Mol Pharmacol 38:689–697.PubMedGoogle Scholar
  16. 16.
    Clark AL, Mitchelson F (1976) The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol 58:323–331.PubMedGoogle Scholar
  17. 17.
    Suga H, Ehlert FJ (2010) Investigating the interaction of McN-A-343 with the M2 muscarinic receptor using its nitrogen mustard derivative. Biochem Pharmacol 79:1025–1035.PubMedCrossRefGoogle Scholar
  18. 18.
    Suga H, Figueroa KW, Ehlert FJ (2008) Use of acetylcholine mustard to study allosteric interactions at the M(2) muscarinic receptor. J Pharmacol Exp Ther 327:518–528.PubMedCrossRefGoogle Scholar
  19. 19.
    Tran JA, Chang A, Matsui M et al (2009) Estimation of relative microscopic affinity constants of agonists for the active state of the receptor in functional studies on M2 and M3 muscarinic receptors. Mol Pharmacol 75:381–396.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Pharmacology, School of MedicineUniversity of CaliforniaIrvineUSA

Personalised recommendations